Falko Busse - Bruker President
| BRKR Stock | USD 82.20 0.26 0.32% |
President
Dr. Falko Busse. Ph.D., is President, Bruker BioSpin Group of the Company, Dr. Busse has served as President of the Bruker BioSpin Group since May 2018, with responsibility for management of its global operations. Dr. Busse served as Deputy President of the Bruker BioSpin Group from October 2017 until his appointment as President. From March 2017 to September 2017, Dr. Busse served as Executive Vice President of Research and Development, Operations and Marketing at the Bruker BioSpin Group. Dr. Busse joined the Bruker BioSpin Group in June 2015 and served as Executive Vice President of Research and Development until February 2017. Prior to joining the Bruker BioSpin Group, Dr. Busse served in various managerial roles at Philips Healthcare and its subsidiaries from August 1994 until May 2015, including as General Manager Radiology Solutions, from January 2014 to May 2015, and as General Manager MRTherapy, from August 2009 to December 2013 since 2018.
| Age | 57 |
| Tenure | 6 years |
| Address | 40 Manning Road, Billerica, MA, United States, 01821 |
| Phone | 978 663 3660 |
| Web | https://www.bruker.com |
Bruker Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3367 %, meaning that it created $0.3367 on every $100 dollars invested by stockholders. Bruker's management efficiency ratios could be used to measure how well Bruker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 04/25/2024, Return On Assets is likely to grow to 0.11, while Return On Capital Employed is likely to drop 0.09. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 04/25/2024, Intangibles To Total Assets is likely to grow to 0.23, while Intangible Assets are likely to drop slightly above 196.5 M.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Peter Delange | ReShape Lifesciences | 47 | |
| Paul Hickey | ReShape Lifesciences | 59 | |
| Kevin Condrin | ReShape Lifesciences | N/A | |
| Naqeeb Ansari | ReShape Lifesciences | 63 | |
| Jona Zumeris | NanoVibronix | 62 | |
Management Performance
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.077 |
Bruker Leadership Team
Elected by the shareholders, the Bruker's board of directors comprises two types of representatives: Bruker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bruker. The board's role is to monitor Bruker's management team and ensure that shareholders' interests are well served. Bruker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bruker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Miroslava Minkova, IR Contact Officer | ||
| Gilles Martin, Independent Director | ||
| Marc Kastner, Independent Director | ||
| Collin DSilva, Pres Division | ||
| Anthony Mattacchione, Interim CFO and Sr. VP of Fin. and Accounting | ||
| Falko Busse, President of the Bruker BioSpin Group and Executive Officer of the Company | ||
| Urban Faeh, Pres GmbH | ||
| Michael Knell, Vice President - Finance, Chief Accounting Officer | ||
| Mark Munch, President of Bruker Nano Group | ||
| Brent JD, General Secretary | ||
| Hermann Requardt, Director | ||
| WolfDieter Emmerich, Independent Director | ||
| Juergen Srega, President of Bruker Daltonics Division and President of Bruker Calid Group | ||
| Stephen Fesik, Independent Director | ||
| John Ornell, Director | ||
| Adelene Perkins, Independent Director | ||
| Cynthia Friend, Independent Director | ||
| Burkhard Prause, President and CEO, BEST | ||
| Christopher Ingen, Independent Director | ||
| Justin Ward, Senior Development | ||
| Rene Lenggenhager, President - Bruker BioSpin Group | ||
| Stacey Desrochers, Treasurer Relations | ||
| Brenda Furlong, Independent Director | ||
| Frank Laukien, Chairman, CEO and Pres | ||
| Richard Kniss, Independent Director | ||
| William Linton, Lead Independent Director | ||
| Gerald Herman, Interim CFO, Principal Accounting Officer | ||
| Joshua Young, Vice President of Investor Relations | ||
| Richard Packer, Independent Director | ||
| Robert Rosenthal, Director | ||
| Joerg Laukien, Director | ||
| Bernd Gewiese, Co-President of Bruker BioSpin Corporation | ||
| Werner Maas, Co-President of Bruker BioSpin Corporation |
Bruker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bruker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.077 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 12.24 B | ||||
| Shares Outstanding | 145.34 M | ||||
| Shares Owned By Insiders | 33.17 % | ||||
| Shares Owned By Institutions | 77.66 % | ||||
| Number Of Shares Shorted | 3.32 M | ||||
| Price To Earning | 67.10 X |
Bruker Investors Sentiment
The influence of Bruker's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bruker. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Bruker's public news can be used to forecast risks associated with an investment in Bruker. The trend in average sentiment can be used to explain how an investor holding Bruker can time the market purely based on public headlines and social activities around Bruker. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bruker's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bruker's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bruker's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bruker.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bruker in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bruker's short interest history, or implied volatility extrapolated from Bruker options trading.
Pair Trading with Bruker
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bruker position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bruker will appreciate offsetting losses from the drop in the long position's value.Moving against Bruker Stock
| 0.81 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.79 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
| 0.5 | EYPT | Eyepoint Pharmaceuticals Downward Rally | PairCorr |
| 0.47 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.42 | ETON | Eton Pharmaceuticals Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bruker could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bruker when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bruker - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bruker to buy it.
The correlation of Bruker is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bruker moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bruker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bruker can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bruker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Bruker Stock, please use our How to Invest in Bruker guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Bruker Stock analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| CEOs Directory Screen CEOs from public companies around the world |
Is Bruker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bruker. If investors know Bruker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bruker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.127 | Dividend Share 0.2 | Earnings Share 2.9 | Revenue Per Share 20.249 | Quarterly Revenue Growth 0.206 |
The market value of Bruker is measured differently than its book value, which is the value of Bruker that is recorded on the company's balance sheet. Investors also form their own opinion of Bruker's value that differs from its market value or its book value, called intrinsic value, which is Bruker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bruker's market value can be influenced by many factors that don't directly affect Bruker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bruker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bruker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bruker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.